A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

• Главные авторы: Nicholas S. Jones (Автор), Smita Kshirsagar (Автор), Vishnu Mohanan (Автор), Vidya Ramakrishnan (Автор), Flavia Di Nucci (Автор), Ling Ma (Автор), Jialin Mao (Автор), Hao Ding (Автор), Sha Klabunde (Автор), Domagoj Vucic (Автор), Lin Pan (Автор), Annemarie N. Lekkerkerker (Автор), Yuan Chen (Автор), Michael E. Rothenberg (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2023-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α, Toll‐like receptors, and ischemic tissue damage. RIP1...